Ad
related to: Financial Advisor and Cancer
Search results
9 Women-Run Companies to Invest In
Investopedia· 6 days agoWomen-owned companies in the U.S. are growing at more than double the rate of all other firms. As women gain a bigger stake in the corporate world, there...
Unum Group (NYSE:UNM) Receives $57.38 Consensus PT from Brokerages
ETF DAILY NEWS· 7 days agoUnum Group (NYSE:UNM – Get Free Report) has received a consensus rating of “Moderate Buy” from the...
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey...
Morningstar· 2 days agoNumab Therapeutics AG (Numab), a clinical stage biotechnology company advancing a proprietary pipeline of immunology and oncology therapeutics, announced today that the Company has entered into ...
GlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.com
ETF DAILY NEWS· 7 days agoStockNews.com assumed coverage on shares of GlycoMimetics (NASDAQ:GLYC – Free Report) in a research note released on Wednesday. The firm issued a sell rating on the biotechnology company’s stock ...
CryptoHeap Launches Comprehensive Staking Services for Cryptocurrency Enthusiasts
Digital Journal· 2 days agoIt is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency ...
How to File a Life Insurance Claim
US News & World Report· 6 days agoOne of the first things you’ll need to do to file a life insurance claim is to get a copy of the deceased’s death certificate. Keep in mind that not just anyone can order a death certificate ...
Bristol-Myers Squibb (NYSE:BMY) Shares Down 1.1%
ETF DAILY NEWS· 5 days agoShares of Bristol-Myers Squibb (NYSE:BMY – Get Free Report) fell 1.1% during trading on Thursday . The company traded as low as $41.58 and last traded at $41.89. 3,501,801 shares changed hands ...
Billionaire Ken Griffin Is Buying These Dividend Stocks Hand Over Fist. Should You?
Motley Fool via Yahoo Finance· 6 days agoThe biggest worry is with Keytruda, whose U.S. patent expires in 2028. The cancer therapy generated...
Should You Buy This Stock After a Regulatory Setback?
Motley Fool via Yahoo Finance· 4 days agoModerna might not have a 100% success rate -- no biotech does. But it has enough "shots on goal,"...
2 Biotech Stocks to Buy in May
Motley Fool via Yahoo Finance· 4 days agoMeanwhile, Regeneron has plenty of exciting pipeline candidates, especially in oncology. The company's financial results will improve substantially...
